Introduction
The t(10;11)(p13;q14-21) is a recurrent translocation found in acute myeloid leukemias (AML) and T-ALL. This translocation fuses CALM (Clathrin-Assembly protein-like Lymphoid-Myeloid leukemia gene, also called PICALM or CLTH) to AF10 (also called MLLT10). [1] [2] [3] The presence of the CALM-AF10 fusion transcript is associated to immature features along lymphoid and myeloid differentiation and to poor prognosis, 3 similar to that found in acute leukemias (AL) with MLL (mixed lineage leukemia gene, also called HRX, HTRX, TRX1 or ALL-1) translocations. 2 CALM was first identified as the partner of AF10 in t(10;11)(p13;q14-21) leukemias. 1 CALM is an ubiquitously expressed 652 amino-acid (aa) protein containing an Epsin N-terminal homologous (ENTH) motif, which mediates the interaction with clathrin during endocytosis. 4 Defective CALM function blocks hematopoiesis and iron metabolism due to defective transferrin endocytosis. 5 The ENTH domain is maintained in all CALM-AF10 fusion proteins. CALM has also been shown to be fused to MLL, in a unique case of t(10;11)(p13;q23) observed in an infant AML. 6 AF10 was first identified as a fusion partner of MLL in AMLs. 7, 8 AF10 is expressed ubiquitously and codes for a protein of 1027 aa. AF10 functions as transcription factor, binding DNA through an AT-hook motif.
9 AF10 contains two zinc-fingers and one bipartite nuclear location signal, both located in the N-terminal region, and a leucine zipper domain and a glutaminerich domain in the C-terminal region. 9, 10 The C-terminal leucine zipper domain is conserved following AF10 fusion to MLL or CALM and has been demonstrated to be essential to the transformation properties of the MLL-AF10 fusion protein. 11, 12 The analyses of rare cases of t(10;11) with the expression of CALM-AF10 but not of the AF10-CALM reciprocal transcript indicated that CALM-AF10 transcripts encode the crucial fusion transcript. 3 Indeed, retroviral expression of CALM-AF10 was reported to induce biphenotypic AL in mice (Deshpande A et al. Blood 2003;102: 216a; abstract #758). We recently reported CALM-AF10 fusion in 9% of T-ALL, restricted to TCRgdexpressing and immature cases (IM, defined by the expression of cytoplasmic CD3 and CD7 and the absence of cytoplasmic TCRb or a TCR). 13, 14 To gain insight into the consequences of the expression of the CALM-AF10 fusion transcript, we performed microarray analysis to compare TCRgd-expressing and immature T-ALL samples, with and without CALM-AF10 fusion transcripts. We show here that CALM-AF10 þ T-ALL are associated with elevated expression of a subset of HOXA genes and some of their transcriptional and functional regulators, as well as a specific overexpression of the oncogene BMI1.
Materials and methods

T-ALL samples used for DNA microarray analysis
In all, 23 T-ALL samples with greater than 90% blasts (except for sample T135) were analyzed using Affymetrix U133A microarrays (Table 1) . They include 14 adults and nine children aged 15 years or less. Four cases were purified using either positive (CD34 þ for UPN4925) or negative (CD3À for UPN1439, UPN792 and UPN3954) selection. Six CALM-AF10 þ T-ALL cases (four IM, two TCRgd þ ) with four different breakpoints, as detailed in Table 1 , were analyzed. These samples were compared to 17 CALM-AF10À T-ALL cases with similar phenotypic features (Table 1) . They included nine IM T-ALL, three TCRgd þ T-ALL and five cases likely to be IM T-ALL based on a sCD3À, CD4À, CD8À, CD1aÀ phenotype. Nine out of 13 tested were LYL1 þ by quantitative RT-PCR, one out of 23 was HOX11L2 þ (UPN3580) and none of 18 analyzed were HOX11 þ or SIL-TAL1. One out of 18 patients tested by Southern for MLL was rearranged (UPN3776, MLL-AF6 þ ).
DNA microarray procedure and gene expression analysis
DNA microarray analysis was performed as described previously. 15 Briefly, total RNA was isolated using RNeasy columns according to the manufacturer's instructions (Qiagen, Hilden, Germany). Double strand (ds) cDNA was then generated from 2 to 5 mg of RNA using SuperScript reverse transcriptase and a T7-oligo(dT) primer. An ENZO kit (Farmingdale, NY, USA) was used to convert the ds cDNA template into biotinylated cRNA utilizing T7 RNA polymerase and biotinylated ribonucleotides. The biotinylated cRNA was then cleaned from enzymes and unincorporated nucleotides using RNeasy 'clean-up' spin columns (Qiagen). An adjusted cRNA yield was calculated to correct for carryover of unlabeled total RNA. cRNA (11 mg) was fragmented and 10 mg of fragmented cRNA was subsequently hybridized to a U133A microarray (Affymetrix, Santa Clara, CA, USA) for 16 h at 451C. After washing and staining with PEconjugated streptavidin, the array fluorescence was determined using a HP/Affymetrix scanner.
The fluorescences of the U133A chips were analyzed using dChip 1.3 software (http://www.dchip.org/ and Li and Wong 16 ). A supervised analysis based on CALM-AF10 fusion was performed after normalization using standard settings of dChip (experiment/baseline ratio higher or lower than 1.2 using lower 90% confidence bound of fold change, experiment (or baseline for lower expression) minus baseline (or experiment) higher than 100 and P-value for testing experiment ¼ baseline lower than 0.05). Microarray data are available from Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; 17 GSE2117 CALM-AF10 T-ALL series; individual accession numbers from GSM38216 to GSM38238).
Quantitative RT-PCR analyses
In all, 37 T-ALL samples (10 CALM-AF10 þ IM/TCRgd þ T-ALL and 27 CALM-AF10À T-ALL (five IM, nine TCRgd, 11 TCRab lineage and two not classified)) different from those used for the microarray experiments and 19 MLL-translocated acute leukemias (MLL-t AL) including five B-cell lineage ALL with MLL-AF4 and 14 AML (two MLL-AF6, six MLL-AF9, two MLL-AF10, three MLL-ELL and one MLL-ENL) were quantified using Taqman quantitative RT-PCR for HOXA5, HOXA9, HOXA10, ANXA2, BMI1, DNAJC1, COMMD3, SPAG6, CD69, NBS1 and MEIS1 (Supplementary Table 1 ). HOXA Taqman probe sets were selected for optimal specificity, with the forward primer and the probe being located in the first exon and the reverse primer in the second exon. RNA was reverse transcribed as described. 18 cDNA quality was checked using ABL and GUSB as control genes. 18 cDNA with ABL C t values higher than 30 were discarded. The expression of each gene was defined by calculating the ratio of expression of the gene of interest to the average of ABL and GUSB values. Quantitative RT-PCR was performed as described 18 using an AppliedBiosystems 7700 PCR machine (Foster City, CA, USA).
Southern blot analysis of CDKN2A (p16 INK4A /p19 ARF ) deletions Southern blot analysis was performed as described previously. 19 In all, 15 mg of isolated DNA were digested with EcoRI (Invitrogen). Restriction fragments were size separated in a Site from which the sample was taken is indicated: PB ¼ peripheral blood; BM ¼ bone marrow. Purification steps prior to hybridization on microarrays are indicated with the selection process (either positive for CD34 or negative for CD3). Breakpoints of CALM-AF10 are indicated.
0.7% agarose gel and transferred by vacuum blotting to a Nytran SuPerCharge membrane (Schleicher & Schuell Bioscience GmbH, Dassel, Germany), which was subsequently hybridized with a 32 P-labeled CDKN2A exon 2 probe. 20 
Results
Genes underexpressed in CALM-AF10 þ T-ALL
In the aim to understand the oncogenic process of CALM-AF10 in T-ALL, we performed a microarray analysis comparing six CALM-AF10 þ T-ALL to 17 CALM-AF10À T-ALL with comparable phenotypic characteristics. Supervised analysis of the microarrays identified 102 probe sets, corresponding to 89 genes, which were significantly (Po0.05) underexpressed in CALM-AF10 þ T-ALL compared to the other T-ALL samples ( Figure 1a ). Nine genes were detected by more than one probe set: AKR7A2, KIAA0368, NCF4, PLXND1, PRSS2, QKI, TNFSF10 and TRA1 (twice each) and NCR3 (six times). For all these nine genes, the different probe sets representing the same gene were always adjacent in the tree view ( Figure 1a ). The five genes most significantly associated with CALM-AF10À T-ALL (Pp0.001) were GGH, ARL6IP4, NBS1, OGFR and TUBB. The five genes with the highest ratio between CALM-AF10 þ and CALM-AF10À T-ALL were PRSS3 (18.4-fold lower in CALM-AF10 þ T-ALL), UBE2E3 (nine-fold lower), PRSS2 (7.8-fold lower), IGJ (6.1-fold lower) and S100A8 (3.6-fold lower). Noteworthy, genes with lower expression in CALM-AF10 þ T-ALL include CDK4, coding for a cycle-dependent kinase, CSF3R, coding for the G-CSF receptor, FANCL, coding for an ubiquitin E3 ligase mutated in Fanconi anemia, ICSBP1, coding for a protein involved in the interferon response, IFI16, coding for an interferon-inducible protein specifically expressed in lymphoid cells, LMO4, coding for a LIM only protein that is mainly expressed in T cells and neural cells, MCM2, MCM5 and MCM7, coding for members of a complex that licences the cell to do a replication cycle, NBS1, coding for a protein that is involved in DNA ds breakage repair and which is deficient in the Nijmegen breakage syndrome, NKG7, coding for a protein highly expressed in T and NK cells, POLD1, coding for the DNA polymerase delta whose mutation is associated with a mutator and cancer phenotype, PRSS2, coding for a trypsin and located inside the TCRB locus, TNFSF10, mainly known as TRAIL, coding for a ligand of TNF, which induces apoptosis when bound to TNF and TYROBP, coding for a protein containing an ITAM (Immunoreceptor Tyrosine-based Activation Motif) region.
The CALM gene itself is detectably underexpressed in CALM-AF10 þ T-ALL (1.6-fold lower). The CALM probe set, 212506_at, is located in the final CALM exon 20, which is missing in all CALM-AF10 fusion transcripts identified so far.
Genes overexpressed in CALM-AF10 þ T-ALL
Supervised analysis of the microarrays revealed that 48 out of 22 215 probe sets, corresponding to 44 genes, were significantly (Po0.05) overexpressed in CALM-AF10 þ T-ALL when compared with CALM-AF10À T-ALL (Figure 1b) . Three genes were identified by more than one probe set: HOXA9, HOXA10 (twice each) and ANXA2 (three times). The different probe sets representing each of these genes were always adjacent in the tree view (Figure 1b) . The five genes with the most significant association with CALM-AF10 þ T-ALL were HOXA9 (twice), BMI1, SOX4, SFRS6 and COMMD3 (Pp0.001). The five genes with the highest ratio between CALM-AF10 þ and CALM-AF10À T-ALL were TUBB (7.2-fold higher in CALM-AF10 þ T-ALL), HOXA9 (twice, 4.1-and 3.4-fold higher), HOXA5 (3.4-fold higher), PNMA2 (2.8-fold higher) and TCF8 (2.7-fold higher). Three HOXA genes, HOXA5, HOXA9 and HOXA10, were identified as overexpressed. HOXA5 and HOXA9 are clustered together in the tree view, whereas HOXA10 is located at the other end of the tree (Figure 1b) . Two overexpressed genes, BMI1 and COMMD3 (also known as BMI1 upstream protein), are located at the 10p12.2 chromosomal band, the region of AF10 breakpoint and are clustered close to each other within the same branch (Figure 1b) . Finally, TUBB was found twice in the array analysis, once underexpressed (probe set 212320_at) and once overexpressed (probe set 204141_at) in CALM-AF10 þ T-ALL. The b-tubulin genes constitute a large family of genes with up to 20 members. 21 The probe set 212320_at matches completely with the TUBB gene located in 6p21.33 in the final exon and also with two pseudogenes in 13q14.11 and 1p32.3. The probe set 204141_at matches completely only with the TUBB gene located in 6p25, in the final exon. These two probe sets did not crosshybridize with each other according to Blast analysis. So, one TUBB gene located at 6p25 is significantly overexpressed in CALM-AF10 þ T-ALL, and one, probably located at 6p21.33, is significantly underexpressed (although signal coming from pseudogenes cannot be formally excluded).
Noteworthy, genes overexpressed in CALM-AF10 þ T-ALL include BMI1, coding for a member of the Polycomb (PcG) family, CD69, coding for an early T-cell activation antigen, CDKN1B (also known as KIP1), coding for a CDK inhibitor, FTH1, coding for the ferritin heavy chain, GADD45A, coding for a gene induced by p53, HOX genes (HOXA5, HOXA9 and HOXA10), JUNB, coding for a transcription factor, PIK3R1 (also known as p85), coding for a regulatory chain of the phosphatidylinositol 3 kinase, PSCD1, coding for a gene specifically expressed in T and NK cells, SKIL, coding for an oncogene also known as SNO, involved in the TGFb pathway regulation, SOX4, a frequent retroviral integration site involved in mouse retroviral insertional mutagenesis and TCF8, coding for a negative regulator of interleukin-2 expression.
HOX expression in CALM-AF10 þ T-ALL As CALM-AF10 expression appeared to be associated with overexpression of HOXA5, HOXA9 and HOXA10 genes, we analyzed more precisely the expression of HOX genes using data coming from the microarrays. We extracted the normalized fluorescence of all HOX genes present on the U133A chip, calculated the average and the standard error for CALM-AF10 þ and CALM-AF10À cases and plotted it according to their genomic location. Only six HOX genes out of 39 are absent from the U133A microarray (Figure 2, Supplementary Table 2 ). HOXA5, HOXA9 and HOXA10 were clearly overexpressed when compared to the other members of the HOXA cluster. Surprisingly, HOXA6 and HOXA7, which are located between HOXA5 and HOXA9, were not overexpressed. None of the paralogous genes for HOXA5 (HOXB5, HOXC5), HOXA9  (HOXB9, HOXD9) and HOXA10 (HOXC10, HOXD10) were overexpressed in CALM-AF10 þ T-ALL. A slight underexpression of HOXB9, HOXC11 and HOXC13 was seen (Figure 2,  Supplementary Table 2) . Therefore, the overexpression of HOX genes in CALM-AF10 þ T-ALL seems to be restricted to HOXA5, HOXA9 and HOXA10, as judged from microarray data analyses. Tables indicate the Affymetrix U133A probe set accession numbers, the genes, the GenBank accession numbers, the chromosomal locations, the mean and standard error of the normalized fluorescences of CALM-AF10 þ and CALM-AF10À T-ALL samples, the fold changes between these two categories and the P-value generated by a t-test, as performed by dChip software.
CALM-AF10 þ T-ALL transcriptional profile WA Dik et al
Overexpression of HOXA5, HOXA9 and HOXA10 by independent analysis in CALM-AF10 þ T-ALL Owing to the important role of genes such as HOXA and BMI1 in oncogenesis, we decided to validate the association between CALM-AF10 and genes overexpressed according to the microarray analysis by quantitative RT-PCR in an independent group of T-ALL samples composed of 10 CALM-AF10 þ and 27 CALM-AF10À T-ALL samples (14 IM/TCRgd and 11 TCRab lineage cases). As HOXA overexpression was previously shown to be associated with MLL-t AL, [22] [23] [24] [25] [26] an additional set of 19 MLL-t AL samples was also analyzed.
HOXA5, HOXA9 and HOXA10 expression levels (medians of 134, 197 and 126%, respectively) were significantly higher in CALM-AF10 þ than in CALM-AF10À T-ALL samples (medians of 0% (Po0.001, using a Mann-Whitney U-test for an identical hypothesis), 2% (Po0.001) and 0% (Po0.001), respectively, Figure 3a and Supplementary Table 3) , thus confirming our microarray data. The expression remained significantly different when CALM-AF10 þ T-ALL were compared separately to CALM-AF10À IM/TCRgd or TCRab lineage T-ALL samples.
Importantly, expression levels of HOXA5, HOXA9 and HOXA10 in CALM-AF10 þ T-ALL were similar to those detected in MLL-t AL samples (medians of 61% (P ¼ 0.164), 223% (P ¼ 0.668) and 119% (P ¼ 0.875), respectively, Figure 3a and Supplementary Table 3 ). Together, these data confirm that CALM-AF10 þ T-ALL are significantly associated with HOXA5, HOXA9 and HOXA10 overexpression, and in that respect resemble to MLL-t AL.
Overexpression of MEIS1 in CALM-AF10 þ T-ALL
MEIS1 expression is tightly associated to HOXA9 expression in MLL-t AL [27] [28] [29] and encodes an essential cofactor of HOXA9 function in normal and malignant processes. Owing to the close relationship between HOXA9 and MEIS1, we decided to quantify MEIS1 expression. Although MEIS1 was not identified using stringent statistical assays, its expression level accessed by microarray showed a 1.9-fold increase in CALM-AF10 þ T-ALL with respect to CALM-AF10À samples T-ALL (data not shown). In the independent cohort of AL samples, MEIS1 expression was significantly higher in CALM-AF10 þ T-ALL compared to CALM-AF10À T-ALL and MLL-t AL (medians of expression of 386%, 2%, (Po0.001) and 144% (P ¼ 0.035), respectively, Figure 3a and Supplementary Table 3 ). The expression was also significantly different when CALM-AF10 þ T-ALL were compared separately to either CALM-AF10À IM/TCRgd or TCRab lineage T-ALL samples. We therefore demonstrate that the association between HOXA9 and MEIS1 expression described in MLL-t AL is also found in CALM-AF10 þ T-ALL.
Overexpression of BMI1 by independent analysis in CALM-AF10 þ T-ALL
Beside HOXA genes, we were interested to confirm the overexpression of BMI1 in CALM-AF10 þ T-ALL as BMI1 was shown recently to be essential to the proliferation of leukemic stem cells. 30 , 31 We quantified BMI1 expression levels on the
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CALM-AF10 þ T-ALL transcriptional profile WA Dik et al same independent cohort used for the quantification of HOXA genes. BMI1 expression in CALM-AF10 þ T-ALL was significantly higher than in CALM-AF10À T-ALL (medians of expression of 1099% and 196% (Po0.001), Figure 3a and Supplementary Table 3 ). The expression was also significantly different when CALM-AF10 þ T-ALL were compared separately to either IM/TCRgd or TCRab lineage CALM-AF10À T-ALL samples. BMI1 expression in CALM-AF10 þ samples was also higher than in MLL-t AL samples (median of 61% (Po0.001)). Noteworthy, the two MLL-AF10 samples analyzed in the MLL-t AL group had a BMI1 expression of 296 and 42%, lower than the median of expression in CALM-AF10 þ samples and within the range of values from the MLL-t AL group. BMI1 is therefore specifically overexpressed in CALM-AF10 þ T-ALL.
Overexpression of genes close to the der(10) breakpoint by quantitative RT-PCR
The BMI1 gene is located close to the AF10 gene on chromosome 10, as is COMMD3, which was also overexpressed in CALM-AF10 þ T-ALL. For that reason, we decided to investigate the expression of the genes located within a 500 kb genomic area of chromosome 10, between AF10 and SPAG6 (a gene immediately centromeric to BMI1; see Figure 3b ). This region contains four genes, DNAJC1, COMMD3, BMI1 and SPAG6 (Figure 3b ).
The expression of all four genes (DNAJC1, COMMD3, BMI1 and SPAG6) was significantly increased in CALM-AF10 þ T-ALL compared to CALM-AF10À T-ALL (medians of expression of 168% vs 35% (P ¼ 0.005), 167% vs 75% (P ¼ 0.003), 1099% vs 196% (Po0.001), 144% vs 1% (Po0.001), respectively). This result is in keeping with an upregulation resulting from a cisactivation effect due to the vicinity of the translocation breakpoint (Supplementary Table 3 and Figure 3b ).
The CDKN2A locus encodes the cell cycle regulators and tumor suppressors p16 INK4A and p19 ARF and BMI1 has been demonstrated to be a potent negative regulator of this locus. 32 As CDKN2A is usually deleted in more than 70% of T-ALL, 33 we decided to verify if this main target of BMI1 was conserved in CALM-AF10 þ T-ALL. Owing to limited amounts of DNA, the CDKN2A locus could only be examined in 13 T-ALL cases of which four contained a CALM-AF10 fusion. Southern blot analysis revealed that the locus was maintained in all tested CALM-AF10 þ T-ALL samples, while it was deleted in six out of nine CALM-AF10À T-ALL. As described previously, CDKN2A deletions in the CALM-AF10À T-ALL cases were accompanied by deletions of the CDKN2B locus (encoding p15 INK4B ), which is also recognized by the probe used. 
Discussion
We demonstrated in this study that CALM-AF10 T-ALL are characterized by overexpression of HOXA5, HOXA9, HOXA10, MEIS1 and BMI1.
Bona fide transcription factors of the homeobox family (HOX genes) share 61 aa helix-turn-helix DNA-binding domain, the homeodomain 34 and are clustered in four genomic regions (HOXA, HOXB, HOXC and HOXD) , containing a total of 39 different HOX genes grouped in 13 paralogous groups. Their The ratio of genes expression relative to two ubiquitously expressed genes (GUSB and ABL) was calculated for each sample. Three categories of samples are compared: CALM-AF10 þ T-ALL (CA þ , n ¼ 10), CALM-AF10À T-ALL (CAÀ, n ¼ 27) and MLL-t AL (MLL, n ¼ 19). Results are presented as a box plot graph using a logarithmic scale. The boundary of the box closest to zero indicates the 25th percentile, a line within the box marks the median, and the boundary of the box farthest from zero indicates the 75th percentile. Narrow horizontal bars above and below the box indicate the 90th and 10th percentiles. Outliers are indicated as dots, but are included in the calculation. P-values of the results are indicated only if significant (Po0.05), otherwise labeled as NS (nonsignificant), at the top using a Mann-Whitney U-test for an identical hypothesis. At the bottom of (b), the genomic organization around the AF10 breakpoint is presented either as germline (upper) or translocated (lower). expression is tightly controlled at the transcription level. The involvement of HOX genes during normal and malignant cellular proliferation has been demonstrated in experimental models and in humans. In mice, the homozygous deletion of HOXA9 exclusively disrupted hematopoiesis, reducing the number of leukocytes, lymphocytes and thymocytes, without affecting the number of earlier progenitors. 35, 36 Overexpression of HOXA9 induces myeloid leukemias, as demonstrated by retroviral insertional mutagenesis in BXH2 mice 28 and retroviral transfection of HOXA9 in mouse bone marrow. 37 Overexpression of HOXA9 was shown to enhance myelopoiesis and to block the differentiation of B cells but not T cells. 38 Specific overexpression of HOXA9 directed to B or T cells did not induce leukemia, suggesting that HOXA9 per se is preferentially a myeloid oncogene. 38 In humans, HOX genes, especially HOXA9, have clearly been shown to be upregulated in MLL-t AL samples. [22] [23] [24] [25] [26] Transformation by MLL-ENL was shown to be dependent on HOXA9. 39 In keeping with this observation, wild-type MLL binds directly to the HOXA9 promoter and methylates histone H3 at lysine by its C-terminal SET domain. [40] [41] [42] More directly, HOX genes are overexpressed after fusion with T-cell receptor genes in T-ALL 43, 44 or when fused to the NUP98 gene 45, 46 as a result of chromosomal translocations. Our results demonstrate a clear association of HOXA5, HOXA9 and HOXA10 overexpression in T-ALL and the CALM-AF10 fusion gene, indicating a common target between MLL-t and CALM-AF10 oncoproteins. Recently, leukemic transformation by MLL-AF10 was shown to be mediated by the recruitment of a methyltransferase, hDOT1L, to its AF10 region. The upregulation of HOXA9 induced by MLL-AF10 was dependent of the MLL binding to the HOXA9 locus and the association of AF10 with hDOT1L. 12 As no obvious DNAbinding domain exists in CALM, the mechanism of activation of HOXA9 by CALM-AF10 should be analyzed further.
HOXA9 function is modulated by interaction with several cofactors like MEIS1. MEIS1 is a member of the TALE (3 aa loop extensions) homeodomain proteins composed of MEIS1, MEIS2, MEIS3, PBX1, PBX2, PBX3 and PREP1/KNOX1. 28, 37, 47, 48 Coinfection of HOXA9 and MEIS1 enhances the capacity of myeloid transformation by HOXA9 37 and synergistically blocks myeloid differentiation. 49 Probably due to the relatively small size of our population, upregulation of MEIS1 was not identified upon stringent statistical criteria used for the analysis of our microarray data (despite a 1.9-fold increase in CALM-AF10 þ T-ALL). However, in our study overexpression of MEIS1 in CALM-AF10 þ T-ALL was clearly demonstrated by quantitative PCR on a larger number of samples, demonstrating a very strong association between HOXA9 and MEIS1. In addition to HOXA9, CALM-AF10 þ T-ALL also overexpressed HOXA5 and HOXA10. Overexpression of HOXA10 has previously been shown to interfere with myeloid and lymphoid differentiation and can induce AML. 50, 51 Recently, HOXA10 was also found to be one of the most prominent transcriptional activation targets in T-ALL that harbor fusions between TCRB and the HOXA cluster. 43, 44 Together, these observations strongly support a role for HOXA genes in T-ALL oncogenesis.
Overexpression of HOXA9 and MEIS1 is a recurrent feature of MLL fusion leukemia, but upregulation of BMI1 has not been reported in MLL-translocated samples. We demonstrated here that the overexpression of BMI1 is a unique feature of CALM-AF10 þ T-ALL. BMI1 was first identified as a target in retroviral mutagenesis, inducing T-cell lymphoma in association with c-MYC. 52 Recently, BMI1 was shown to be essential to the selfrenewal of normal and leukemic stem cells. 30, 31, 53 The BMI1 protein is part of a Polycomb complex including also MEL18, Mph1/Rae28, M33, SCMH1 and Ring1A/B. 53 BMI1 is the only member of this complex that is specifically upregulated in CALM-AF10 þ T-ALLs (data not shown). Keeping with this result, BMI1 was shown to be the only Polycomb gene whose forced expression was associated with a marked increase of selfrenewal of hematopoietic stem cells.
53
BMI1 controls cellular proliferation by inhibiting the expression of the CDKN2A locus that encodes the tumor suppressors p16 ink4a and p19 arf . 32 CDKN2A is more frequently deleted in T-ALL than in other subtypes of AL, namely in more than 70% of cases. 20 Such a deletion would obviously preclude an antiproliferative effect of BMI1 in the CALM-AF10 þ samples. However, using Southern blot analysis, we found no CDKN2A deletion in CALM-AF10 þ T-ALL. This suggests that overexpression of BMI1 has functional effects similar to that of CDKN2A deletion.
In CALM-AF10 þ T-ALL, aberrant expression of BMI1 could be due to a cis effect, as the BMI1 gene is located in the vicinity of the chromosome 10 breakpoint. In keeping with this hypothesis, transcriptional cis activation is a classical form of activation in T-ALL. 54 CALM-AF10 þ T-ALL showed overexpression of several AF10 downstream neighboring genes (DNAJC1, COMMD3, BMI1 and SPAG6) located close to the AF10 gene breakpoint. To our knowledge, this is the first study to report on upregulation of genes downstream from a fusion gene in leukemia. From these four AF10 downstream genes, BMI1 is the only one known to be involved in oncogenesis. Two MLL-AF10 AML samples were analyzed in our series, but they did not demonstrate high expression of these genes. In fact, the MLL and AF10 genes lie in an opposite orientation on their respective chromosome and their in-frame fusion requires at least two chromosomal breaks. Therefore, MLL-AF10 translocations are frequently associated with complex karyotypes, rearrangements and deletions at the breakpoints. [55] [56] [57] [58] [59] It is conceivable that t(10;11)(p12;q23) translocation frequently results in the deletion of BMI1 from the translocated chromosome 10 or an opposite orientation regarding MLL-AF10 fusion. Possible deletion of BMI1 by t(10;11)(p12;q23) could be assessed by FISH analysis, but unfortunately we were unable to do so because of lack of material for the two MLL-AF10 cases.
Finally, activation of HOXA genes by CALM-AF10, MLL fusions or HOXA translocations seems to be a common leukemic pathway. The difference of phenotype (myeloid, B-or T-cell markers expression) could merely reflect the stage of maturation arrest, without reflecting the oncogenic mechanism. We propose to define a HOXA þ leukemia group AL HOXA+ Figure 4 The pattern of overexpression in CALM-AF10 þ T-ALL is similar to that of MLL-t AL, essentially overexpression of HOXA genes, as also in AML with NUP98-HOXA9. These fusion genes could be seen as members of a common transformation pathway dysregulating HOXA9 and its downstream targets.
composed of at least MLL-translocated, CALM-AF10 and HOXA-translocated ALs, which may benefit from adapted management (Figure 4 ).
